MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the sale of
common stock in initial...
$157,284K
Proceeds from issuance of
convertible preferred...
$65,228K
Proceeds from exercise of
stock options
$6K
Net cash provided by
financing activities
$220,763K
Canceled cashflow
$1,755K
Net increase
(decrease) in cash, cash...
$29,015K
Canceled cashflow
$191,748K
Taxes paid related to
net share...
$1,224K
Principal payments of
finance lease liability
$373K
Principal payments of
financing obligation
$158K
Maturities of investments
$84,100K
Stock-based compensation
expense
$5,856K
Accrued liabilities
$2,818K
Depreciation and
amortization
$1,389K
Net cash used in
investing activities
-$115,307K
Net cash used in
operating activities
-$76,441K
Canceled cashflow
$84,100K
Canceled cashflow
$10,063K
Purchases of investments
$199,172K
Net loss
-$68,870K
Change in fair value of
convertible preferred stock...
$8,928K
Purchase of property and
equipment
$235K
Deferred revenue
-$3,000K
Prepaid expenses and
other assets
$2,370K
Accretion of discount on
investments
$1,769K
Accounts payable
-$837K
Operating lease
liabilities
-$730K
Back
Back
Cash Flow
source: myfinsight.com
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)